This randomized controlled trial compared the efficacy and safety of three doses of tirzepatide (5 mg, 10 mg, and 15 mg), a dual GLP-1 and GIP receptor agonist, to semaglutide (1 mg), a GLP-1 receptor agonist, in 1879 patients with type 2 diabetes inadequately controlled with metformin alone. The primary outcome was the change in HbA1c from baseline to 40 weeks. Key secondary outcomes included changes in body weight and achievement of HbA1c targets. Tirzepatide at all doses resulted in greater reductions in HbA1c and body weight compared to semaglutide and was found to be noninferior and